Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure

Results from EPHESUS

J. H. O'Keefe, Hussam Abuissa, B. Pitt

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15%, combined cardiovascular (CV) mortality/CV hospitalization by 13%, CV mortality by 17% and sudden cardiac death by 21%, vs. placebo when added to standard care in patients with left ventricular systolic dysfunction (LVSD) and signs of congestive heart failure (CHF) following acute myocardial infarction (AMI). We retrospectively evaluated the effect of eplerenone vs. placebo in a subset of 1483 diabetic patients with LVSD and signs of CHF following AMI. Methods: Diabetic status was determined from medical histories at screening. Analyses were based on time to first occurrence of an event. Results were based on a Cox's proportional hazards regression model stratified by region with treatment, subgroup and treatment-by-subgroup interaction as factors. The 95% confidence intervals for the risk ratios were based on the Wald's test. Results: Treatment with eplerenone in diabetic patients with CHF following AMI reduced the risk of the primary endpoint, a composite of CV mortality or CV hospitalization, by 17% (p = 0.031). The absolute risk reduction of the primary endpoint was greater in the diabetic cohort (5.1%) than in the non-diabetic cohort (3%). Hyperkalaemia occurred more often with eplerenone than with placebo (5.6 vs. 3%, p = 0.015). Among the diabetic cohorts, the prespecified endpoint of 'any CV disorder' occurred in 28% of the eplerenone group and 35% of the placebo group (p = 0.007). Conclusion: Eplerenone treatment may reduce adverse CV events in diabetic patients with LVSD and signs of CHF following AMI.

Original languageEnglish
Pages (from-to)492-497
Number of pages6
JournalDiabetes, Obesity and Metabolism
Volume10
Issue number6
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Infarction
Heart Failure
Myocardial Infarction
Survival
Left Ventricular Dysfunction
Placebos
Mortality
Hospitalization
Numbers Needed To Treat
Hyperkalemia
Sudden Cardiac Death
Therapeutics
Aldosterone
Proportional Hazards Models
eplerenone
Patient Care
Odds Ratio
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure : Results from EPHESUS. / O'Keefe, J. H.; Abuissa, Hussam; Pitt, B.

In: Diabetes, Obesity and Metabolism, Vol. 10, No. 6, 06.2008, p. 492-497.

Research output: Contribution to journalArticle

@article{06a389588225433fb743152cf88aef1c,
title = "Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: Results from EPHESUS",
abstract = "Background: The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15{\%}, combined cardiovascular (CV) mortality/CV hospitalization by 13{\%}, CV mortality by 17{\%} and sudden cardiac death by 21{\%}, vs. placebo when added to standard care in patients with left ventricular systolic dysfunction (LVSD) and signs of congestive heart failure (CHF) following acute myocardial infarction (AMI). We retrospectively evaluated the effect of eplerenone vs. placebo in a subset of 1483 diabetic patients with LVSD and signs of CHF following AMI. Methods: Diabetic status was determined from medical histories at screening. Analyses were based on time to first occurrence of an event. Results were based on a Cox's proportional hazards regression model stratified by region with treatment, subgroup and treatment-by-subgroup interaction as factors. The 95{\%} confidence intervals for the risk ratios were based on the Wald's test. Results: Treatment with eplerenone in diabetic patients with CHF following AMI reduced the risk of the primary endpoint, a composite of CV mortality or CV hospitalization, by 17{\%} (p = 0.031). The absolute risk reduction of the primary endpoint was greater in the diabetic cohort (5.1{\%}) than in the non-diabetic cohort (3{\%}). Hyperkalaemia occurred more often with eplerenone than with placebo (5.6 vs. 3{\%}, p = 0.015). Among the diabetic cohorts, the prespecified endpoint of 'any CV disorder' occurred in 28{\%} of the eplerenone group and 35{\%} of the placebo group (p = 0.007). Conclusion: Eplerenone treatment may reduce adverse CV events in diabetic patients with LVSD and signs of CHF following AMI.",
author = "O'Keefe, {J. H.} and Hussam Abuissa and B. Pitt",
year = "2008",
month = "6",
doi = "10.1111/j.1463-1326.2007.00730.x",
language = "English",
volume = "10",
pages = "492--497",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure

T2 - Results from EPHESUS

AU - O'Keefe, J. H.

AU - Abuissa, Hussam

AU - Pitt, B.

PY - 2008/6

Y1 - 2008/6

N2 - Background: The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15%, combined cardiovascular (CV) mortality/CV hospitalization by 13%, CV mortality by 17% and sudden cardiac death by 21%, vs. placebo when added to standard care in patients with left ventricular systolic dysfunction (LVSD) and signs of congestive heart failure (CHF) following acute myocardial infarction (AMI). We retrospectively evaluated the effect of eplerenone vs. placebo in a subset of 1483 diabetic patients with LVSD and signs of CHF following AMI. Methods: Diabetic status was determined from medical histories at screening. Analyses were based on time to first occurrence of an event. Results were based on a Cox's proportional hazards regression model stratified by region with treatment, subgroup and treatment-by-subgroup interaction as factors. The 95% confidence intervals for the risk ratios were based on the Wald's test. Results: Treatment with eplerenone in diabetic patients with CHF following AMI reduced the risk of the primary endpoint, a composite of CV mortality or CV hospitalization, by 17% (p = 0.031). The absolute risk reduction of the primary endpoint was greater in the diabetic cohort (5.1%) than in the non-diabetic cohort (3%). Hyperkalaemia occurred more often with eplerenone than with placebo (5.6 vs. 3%, p = 0.015). Among the diabetic cohorts, the prespecified endpoint of 'any CV disorder' occurred in 28% of the eplerenone group and 35% of the placebo group (p = 0.007). Conclusion: Eplerenone treatment may reduce adverse CV events in diabetic patients with LVSD and signs of CHF following AMI.

AB - Background: The Epleronone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial demonstrated that selective aldosterone blockade with eplerenone significantly reduced total mortality by 15%, combined cardiovascular (CV) mortality/CV hospitalization by 13%, CV mortality by 17% and sudden cardiac death by 21%, vs. placebo when added to standard care in patients with left ventricular systolic dysfunction (LVSD) and signs of congestive heart failure (CHF) following acute myocardial infarction (AMI). We retrospectively evaluated the effect of eplerenone vs. placebo in a subset of 1483 diabetic patients with LVSD and signs of CHF following AMI. Methods: Diabetic status was determined from medical histories at screening. Analyses were based on time to first occurrence of an event. Results were based on a Cox's proportional hazards regression model stratified by region with treatment, subgroup and treatment-by-subgroup interaction as factors. The 95% confidence intervals for the risk ratios were based on the Wald's test. Results: Treatment with eplerenone in diabetic patients with CHF following AMI reduced the risk of the primary endpoint, a composite of CV mortality or CV hospitalization, by 17% (p = 0.031). The absolute risk reduction of the primary endpoint was greater in the diabetic cohort (5.1%) than in the non-diabetic cohort (3%). Hyperkalaemia occurred more often with eplerenone than with placebo (5.6 vs. 3%, p = 0.015). Among the diabetic cohorts, the prespecified endpoint of 'any CV disorder' occurred in 28% of the eplerenone group and 35% of the placebo group (p = 0.007). Conclusion: Eplerenone treatment may reduce adverse CV events in diabetic patients with LVSD and signs of CHF following AMI.

UR - http://www.scopus.com/inward/record.url?scp=43149121333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149121333&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2007.00730.x

DO - 10.1111/j.1463-1326.2007.00730.x

M3 - Article

VL - 10

SP - 492

EP - 497

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 6

ER -